Job openings for the production department. Job openings in the Production department at GLAND PHARMA LTD. Job for everyone . This is a ...
Job openings for the production department.
Job openings in the Production department at GLAND PHARMA LTD. Job for everyone. This is a great opportunity for fresher or experienced people who want to find jobs in the Pharmaceuticals sector. Your dream city for graduate jobs. Job available for everyone who wants to job nearby your places or area. If you want instant notifications of jobs and fresh news about Government jobs or Private sector jobs. So, join our what's App or Telegram groups. Just a small click changes your life it'll helps you to reach your dream job. You can also like or follow our Facebook group.
Walk-in-interview on July 7th and 9th @Pashamylaram In Gland Pharma Ltd.
Experience needed to 1 to 7 years in Injectable / Parentral experience candidates will be considered.
Key skills: Sterile Injectable, Experience in compounding, Filling, Sealing, Washing, Formulation, Line management, Qms, Sip, Amoule/Autoclave operator, Line chemist, BPCR review.
Walk-in-interview venue: GLAND PHARMA LTD. unit 2 phase 3, industrial park, Pashamylaram, Medak, Telangana 502307
Time: 10 to 2 PM
Interested candidates can send their resume to rahul.roy@glandpharma.com or what app on 9177619464
ABOUT GLAND PHARMA
A holistic objective of dispensing health through a portfolio of injectable products across various therapeutic segments and delivery systems, has helped us expand to seven manufacturing facilities in India, with a capacity of approximately 750 million units. These include four facilities with 22 production lines for finished formulations and three Active Pharmaceutical Ingredient (API) facilities. Our products are produced at world-class manufacturing facilities and conform to global compliance, regulatory and quality specifications.
We are present in sterile injectables, oncology and ophthalmic segments, and focus on complex injectables including NCE-1s, First-to-File products and 505(b)(2) filings. Our products are currently delivered via liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops; and efforts are underway to augment additional manufacturing capabilities in complex injectables such as peptides, long-acting injectables, suspensions and hormonal products. We are also in the process of including new delivery systems such as pens and cartridges into our product portfolio.
Our ethos at work is to consistently focus on meeting diverse injectable needs with high-quality products at attractive price points. On this strong plinth of looking ahead, we have successfully and repeatedly harnessed our R&D expertise in synthesizing complex molecules to produce complex injectables. Enabling us to develop niche products for diverse markets worldwide.
RESEARCH & DEVELOPMENT
Our two state-of-the-art R&D divisions in Hyderabad is staffed by nearly 250 qualified scientists. The labs engage in Formulation Development, Analytical Method Development, API Process Development, and Stability Studies. Our expertise includes the synthesis of complex drug molecules such as LMWH, Corticosteroids, Peptides, and Cytotoxic molecules.
As a vertically integrated company, we have seamlessly combined our expertise in internal research and development (R&D) with state-of-the-art manufacturing set-ups. Together with stringent quality control systems, extensive experience in regulatory procedures established marketing and distribution infrastructure.
Our exemplary regulatory compliance track record can be gauged from the fact that all our facilities are USFDA approved. Other key global approvals include MHRA (UK), EMA (EU), TGA (Australia), ANVISA (Brazil) and BGV Hamburg (Germany).
Synthetic R&D
- Process Development for Niche APIs
- Patent Non-Infringing Process
- Pilot and Scale-Up Studies
- Formulation R&D at gland pharma
- Formulation R&D
Formulation Development
- pre-formulation Studies
- Lyo-Cycle Development and Scale-Up
- Analytical R&D at gland pharma
- Analytical R&D
Analytical Method Development and Validation
Impurity Determination and Characterization
Primary Reference Standard Preparation and Standardization
FORMULATION FACILITIES
Our four best-in-class, cGMP-compliant formulation manufacturing facilities manufacture a wide range of injectables using an aseptic filling or terminal sterilization, as applicable. The facilities are equipped for production flexibility and can switch product lines seamlessly, eliminating the need to install additional production lines to meet altered product specifications and market mechanics of demand and supply.
Our facilities have received accreditations from the following regulatory bodies:
- US FDA (United States Food and Drug Administration)
- UK’s MHRA (United Kingdom’s Medicines and Health products Regulatory Agency)
- BGV Germany (Behörde für Gesundheit und Verbraucherschutz – Hamburg)
- ANVISA Brazil (National Health Surveillance Agency)
- TGA Australia (Therapeutic Goods Administration)
- MCC South Africa (Medicines Control Council)
- WHO (World Health Organization)
- Health Canada
DUNDIGAL, HYDERABAD
Our 600,000 sq. ft. flagship sterile injectable facility in Dundigal, Hyderabad - USFDA approved since 2003 - possesses capabilities across various delivery formats.
6 vials lines with 7 lyophilizers: 240 million units / year & 48 million lyo units / year
1 ampoules line: 60 million units/year
2 Pre-Filled Syringes (PFS) lines -: 60 million units/year
2 Bag Filling line: 5 million units/year
1 Ophthalmic line: 45 million units/year
PASHAMYLARAM, HYDERABAD
The sterile injectable facility in Pashamylaram, Hyderabad, after selling in the domestic since July 2015; obtained USFDA approval in April 2016 and entered the USA market in September 2016. Output at this facility has nearly doubled our manufacturing capacity.
2 vial lines for liquid filling: 132 million units/year
1 vial line with 3 lyophilizers: 18 million units/year
2 ampoule lines: 120 million units/year
Pashamylaram, Hyderabad
Penems, Hyderabad
PENEMS, HYDERABAD
A dedicated Penems facility, after filing its first ANDA in September 2013, obtained USFDA approval in April 2016.
Dry powder line: 4 million units/year
Liquid vial line with two lyophilizers: 8 million to units/year
ONCOLOGY FACILITY, SEZ VISAKHAPATNAM
Our oncology facility after receiving USFDA and GMP (EU) approval in 2014, began sales in Europe in 2015 and in the United States in 2016.
3 Vial lines with 4 lyophilizers ract: 11 million units / year & 5 million lyo units / year
For more info about Government jobs click here to connect me
Join me for more Private Job sector information just click on icons.
For more info about Government jobs click here to connect me
Join me for more Private Job sector information just click on icons.
No comments
If you have any doubts please let me know.